18/09/2023Published by Fondazione Gianni Bonadonna at 18/09/2023Categories Events UncategorizedSHP2 inhibition to overcome resistance to targeted therapies
11/09/2023Published by Fondazione Gianni Bonadonna at 11/09/2023Categories Events UncategorizedDostarlimab in primary advanced or recurrent endometrial cancer
08/09/2023Published by Michele Tartaglione at 08/09/2023Categories Events UncategorizedIs it possible to predict the efficacy of immunotherapy in triple-negative breast cancer?
04/09/2023Published by Fondazione Gianni Bonadonna at 04/09/2023Categories Events UncategorizedAtezolizumab after chemotherapy in resected non-small cell lung cancer
21/08/2023Published by Fondazione Gianni Bonadonna at 21/08/2023Categories Events UncategorizedCamrelizumab plus rivoracenib for unresectable hepatocellular carcinoma
07/08/2023Published by Fondazione Gianni Bonadonna at 07/08/2023Categories Events UncategorizedDeterminants of trastuzumab deruxtecan response in metastatic breast cancer
31/07/2023Published by Fondazione Gianni Bonadonna at 31/07/2023Categories Events UncategorizedA new FGFR2 inhibitor with activity across FGFR2 alterations
24/07/2023Published by Fondazione Gianni Bonadonna at 24/07/2023Categories Events UncategorizedCabozantinib, nivolumab and ipilimumab in advanced renal-cell carcinoma
17/07/2023Published by Fondazione Gianni Bonadonna at 17/07/2023Categories Events UncategorizedTrifluridine-tipiracil plus bevacizumab in metastatic colorectal cancer
